177 related articles for article (PubMed ID: 33870833)
1. Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data.
Chaudhary MA; Holmberg C; Lakhdari K; Smare C; Theriou C; Dale P; Penrod JR
J Med Econ; 2021; 24(1):607-619. PubMed ID: 33870833
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of nivolumab in patients with NSCLC in the United States.
Chaudhary MA; Lubinga SJ; Smare C; Hertel N; Penrod JR
Am J Manag Care; 2021 Aug; 27(8):e254-e260. PubMed ID: 34460179
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Berling M; Chaudhary MA; Yuan Y; Varol N; Dale P; Testa E; Klint J; Lee A; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):703-711. PubMed ID: 35659172
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis.
Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
Clin Drug Investig; 2020 Feb; 40(2):129-137. PubMed ID: 31679121
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.
Goeree R; Villeneuve J; Goeree J; Penrod JR; Orsini L; Tahami Monfared AA
J Med Econ; 2016 Jun; 19(6):630-44. PubMed ID: 26850122
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
Marine S; Stéphane R; Nicolas P; Felizzi F; Paracha N; Benjamin M; Perol M
J Med Econ; 2020 May; 23(5):464-473. PubMed ID: 31951770
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer.
Smare C; Dave K; Juarez-Garcia A; Abraham P; Penrod JR; Camidge DR; Yuan Y
J Med Econ; 2021; 24(1):1124-1133. PubMed ID: 34465261
[TBL] [Abstract][Full Text] [Related]
12. Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models.
Gao L; Li SC
Appl Health Econ Health Policy; 2019 Jun; 17(3):371-380. PubMed ID: 30535675
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Dickson R; Bagust A; Boland A; Blundell M; Davis H; Dundar Y; Hockenhull J; Martin Saborido C; Oyee J; Ramani VS
Pharmacoeconomics; 2011 Dec; 29(12):1051-62. PubMed ID: 21967156
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
Pei R; Shi Y; Lv S; Dai T; Zhang F; Liu S; Wu B
JAMA Netw Open; 2021 May; 4(5):e218065. PubMed ID: 33956130
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
Zhao M; Shao T; Chi Z; Tang W
Front Public Health; 2023; 11():1051484. PubMed ID: 36908446
[TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England.
Rothwell B; Kiff C; Ling C; Brodtkorb TH
Pharmacoecon Open; 2021 Jun; 5(2):251-260. PubMed ID: 33332018
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (
Nilsson FOL; Gal P; Houisse I; Ivanova JI; Asanin ST
J Med Econ; 2021; 24(1):447-457. PubMed ID: 33754924
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer.
Peng Y; Zeng X; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
Adv Ther; 2021 Jul; 38(7):3962-3972. PubMed ID: 34100243
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Vokes EE; Ready N; Felip E; Horn L; Burgio MA; Antonia SJ; Arén Frontera O; Gettinger S; Holgado E; Spigel D; Waterhouse D; Domine M; Garassino M; Chow LQM; Blumenschein G; Barlesi F; Coudert B; Gainor J; Arrieta O; Brahmer J; Butts C; Steins M; Geese WJ; Li A; Healey D; Crinò L
Ann Oncol; 2018 Apr; 29(4):959-965. PubMed ID: 29408986
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan.
Mo X; Moriwaki K; Morimoto K; Shimozuma K
Clin Drug Investig; 2022 Jul; 42(7):599-609. PubMed ID: 35675029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
